| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
4 companies
Friedman Paul A is a Director at PRLD, with reported holdings spanning 4 companies. Recent filings cover 2 purchases and 107 sales. Those positions are worth an estimated $96.0M at current prices.
Our model assigns Friedman Paul A a below-average insider score of 36/100, based on 12 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -42.5%.
Friedman Paul A's largest disclosed position is in MDGL as Director, worth about $96.0M. The recent filings there lean toward selling, a net 421,382 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 20, 2018 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 4,000 | $117.88 | $471,520.00 | +2.5% | |
| Nov 19, 2018 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 4,000 | $124.00 | $496,000.00 | +2.6% | |
| Jun 11, 2018 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Executive Officer | Sell | 73,526 | $287.46 | $21,135,783.96 | -10.1% |